0L49.LSE SCYNEXIS, Inc.

Healthcare Drug Manufacturers - Specialty & Generic London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Is 0L49.LSE undervalued?

Graham number

The Graham number of SCYNEXIS, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SCYNEXIS, Inc. fundamental analysis

No fundamental analysis for SCYNEXIS, Inc. yet.

SCYNEXIS, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SCYNEXIS, Inc.

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS…

Full company profile